The post KITE hits new ATH after 26% surge – More gains ahead? appeared on BitcoinEthereumNews.com. KITE bounced back with strength from a $0.18 slip, clearing The post KITE hits new ATH after 26% surge – More gains ahead? appeared on BitcoinEthereumNews.com. KITE bounced back with strength from a $0.18 slip, clearing

KITE hits new ATH after 26% surge – More gains ahead?

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

KITE bounced back with strength from a $0.18 slip, clearing all February losses. After successfully defending $0.2, the altcoin jumped to a new all-time high of $0.3036

At the time of writing, Kite [KITE] was trading at $0.3099, up 26.29% on the daily charts. This price uptick was backed by 156% jump in trading volume – A sign of greater market participation. 

KITE buyers pile in, defending key levels

After KITE dropped to a low of $0.21 three days ago, buyers stepped in and aggressively bought the dip. In fact, buyers’ strength skyrocketed too while outpacing sellers. In fact, a look at the Buyer Seller Strength metric revealed that buyers have dominated the market for two consecutive days. 

On 5 March, their strength jumped to 86. A day later, it climbed to 93, compared to 6 for sellers. 

Source: Tradingview

The Buyer Seller Dominance further validated these market dynamics. Over this period, Buyer Dominance exceeded 46 million, recording figures of 26 million at press time. 

Traditionally, sustained market demand has strengthened upward momentum, leading to higher prices. 

Profit takers threaten to spoil the party!

As expected, after the altcoin rallied to a new all-time high, holders and investors rushed into the market and cashed out. According to Coinglass, the altcoin’s Exchange Inflows surged to $32.2 million, compared to $30.9 million in outflows. 

Source: Coinglass

As a result, KITE’s Spot Netflows jumped by 215% to $1.28 million. Usually, when netflows are positive, it means more sell-side activity than buy-side activity. 

Such market conditions have tended to cause higher downside pressure as the supply available to sell rises – A prelude to price pullbacks.

What does the momentum indicator say?

KITE reached another high as buyers dominated the market, and profit takers’ attempts proved inadequate to derail the upward momentum. In doing so, its momentum indicators showed a strong bullish bias.

In fact, the Relative Strength Index (RSI) made a bullish crossover and jumped to 64, signaling strong buying pressure in the market. Likewise, the altcoin’s Relative Vigor Index (RVGI) also made a bullish crossover and rose to 0.0192, further validating the trend’s strength.

Source: Tradingview

These two indicators signaled a likelihood of the market trend holding firm if the demand holds. Thus, if bullish sentiment continues to dominate, KITE could establish a solid foundation above $0.3 and eye another ATH.

On the other hand, profit realization remains a serious threat to recent gains. If sellers continue to cash out, sharp downside pressure could drive KITE to $0.23.


Final Summary

  • Kite [KITE] rallied by 26%, hitting a new all-time high of $0.303 on the back of strong bullish momentum. 
  • Profit realization soared as holders sold into the rally, threatening recent gains.
Previous: DeFi Technologies gets Nasdaq warning after shares fall below $1
Next: Pi Network nears crucial price point: Breakout or bull trap for PI?

Source: https://ambcrypto.com/kite-hits-new-ath-after-26-surge-more-gains-ahead/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09